Genfit S.A.

OTCPK:GNFT.Y Rapport sur les actions

Capitalisation boursière : US$541.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Genfit Gestion

Gestion contrôle des critères 3/4

Le PDG Genfit est M. Prigent, nommé en Sep2019, a un mandat de 6.5 ans. La rémunération annuelle totale est € 681.95K, composée du salaire de 59.5% et des bonus 40.5%, y compris les actions et options de la société. détient directement 0.062% des actions de la société, d'une valeur de $ 333.78K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4 ans et 8.8 ans.

Informations clés

M. Prigent

Directeur général

€681.9k

Rémunération totale

Pourcentage du salaire du PDG59.47%
Durée du mandat du directeur général6.5yrs
Propriété du PDG0.06%
Durée moyenne d'occupation des postes de direction4yrs
Durée moyenne du mandat des membres du conseil d'administration8.8yrs

Mises à jour récentes de la gestion

Recent updates

Seeking Alpha • Nov 21

Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions

Summary Genfit's Iqirvo received FDA approval in June 2024 for treating primary biliary cholangitis. Gilead's Livdelzi has shown superior efficacy in reducing alkaline phosphatase levels in PBC patients. Genfit licensed Iqirvo's global rights to Ipsen in 2021, securing milestone payments and royalties. Genfit's pipeline includes VS-01 for acute-on-chronic liver failure and GNS561 for cholangiocarcinoma. Given Iqirvo's competitive challenges and speculative pipeline, Genfit's long-term prospects remain uncertain. Read the full article on Seeking Alpha
Seeking Alpha • Sep 28

Genfit GAAP EPS of -€0.21, revenue of €12.19M

Genfit press release (NASDAQ:GNFT): 1H GAAP EPS of -€0.21. Revenue of €12.19M (+255.4% Y/Y). Shares +3.27%.
Seeking Alpha • Sep 19

Genfit to acquire Swiss-based Versantis focused on liver diseases

Genfit (NASDAQ:GNFT) on Monday announced that it has signed an exclusivity agreement to acquire a private Swiss-based clinical stage biotechnology firm- Versantis - at an initial consideration of CHF 40M. Headquartered in Zurich, Switzerland, Versantis is focused on drug and diagnostic product development for the acute-on-chronic liver failure (ACLF) and other unmet medical needs in liver diseases. Its main asset, VS-01, is claimed as first-in-class innovative liposomal-based therapeutic product candidate currently in clinical development for the timely recovery of ACLF and UCD. If approved, it would be the first drug to use the intraperitoneal route to simultaneously support the liver, kidney and brain, the organs that most often fail in cirrhotic patients. Consideration: This acquisition deal comprises of initial CHF 40M due at closing and consideration of up to CHF 65M upon positive Phase 2 results for VS-01 and VS-02 and regulatory approval of VS-01. Also, Versantis is eligible to receive 1/3 of the net proceeds resulting from the potential sale of the pediatric review voucher of VS-01.  Pascal Prigent, Chief Executive Officer of GENFIT, commented: “Versantis has an exciting portfolio that is complementary to GENFIT’s. We are also thrilled to welcome a talented team that has developed a strong scientific expertise in ACLF. We believe that significant synergies exist and that this acquisition will accelerate the development of several promising drug candidates in areas of high unmet needs.”
Seeking Alpha • Sep 07

Genfit S.A.: A 'Sum Of The Parts' Story

Summary Today, we put France-based biotech concern Genfit S.A. back in the spotlight for the first time in a year and a half. The company has a lot of moving parts and little analyst coverage but seems to be advancing its pipeline forward. An investment analysis follows in the paragraphs below. How can you govern a country which has 246 varieties of cheese?"― Charles de Gaulle We last posted a piece on small biotech outfit Genfit S.A. (GNFT) in March of 2021. We concluded saying the company has some interesting attributes, but it was probably too early to take a stake in its pending further development. The stock trades almost exactly where it did 18 months ago. No one else on Seeking Alpha has covered the company since then. Therefore, we will circle back on this name today. Seeking Alpha Company Overview: This France-based clinical stage biotech concern is focused on developing treatments primarily to treat disease of the liver and from gastroenterology. The shares currently trade just above four bucks a share and sports a market capitalization just north of $200 million. April Company Presentation Genfit is developing several compounds within its pipeline. Elafibranor, a dual agonist of PPARα and PPARδ, has shown encouraging results in mid-stage studies evaluating it to treat Primary Biliary Cholangitis or PBC. Elafibranor has Breakthrough Therapy and Orphan Drug status for PBC it should be noted. In late 2021, the company announced that it entered into an arrangement with Ipsen that will give that drug maker exclusive worldwide license to develop, manufacture and commercialize Elafibranor. April Company Presentation Genfit received a €120 million upfront payment for this license agreement and also can garner milestone payments up to €360 million (roughly 50% of this is for developmental milestones), plus tiered double-digit royalties of up to 20% on any commercialized sales. €80 million of the upfront payment was recognized as revenue in 2021, and €40 million was booked as deferred revenue and will be recognized as revenue in subsequent years following the completion of the ELATIVE double-blind study. Top-line results from that Phase 3 study evaluating Elafibranor to treat PBC should be out in the second quarter of next year. April Company Presentation The company is also working on a simple non-invasive test with Labcorp to identify at risk patients for NASH. This will be important if/when a drug is eventually approved for NASH. The company already has a significant database of patients from the work it did with its own NASH development which ended with the failure of the RESOLVE-IT trial in 2020. More data will be added with Ipsen's work on PBC. April Company Presentation The company is also working with other NASH development trials to ensure they knew steroids in their clinical trials, so that they can generate data with it. They also would naturally allow clients to use this test built on Genfit's NIS4 technology out of five blood based biomarker panels called NASHNext. That will launch from Labcorp if it is eventually approved. Genfit has an exclusive license agreement with LabCorp around this test. Genfit hopes this becomes the standard to identify at-risk NASH patients, provided a drug or drugs is approved for this widespread affliction. April Company Presentation The company also has two Phase 1 studies evaluating a candidate called NTZ, which they identified through phenotypic screening. The first Phase 1 study is focused on hepatic impairment, results from that study should be out shortly. The other Phase 1 study is focused on renal impairment. Data for this trial expected to be available in the fourth quarter of 2022. April Company Presentation Finally, late last year Genfit licensed an investigational compound from Genoscience Pharma called GNS5611. Genfit hopes to launch a Phase 1b/2 study towards the end of this year to evaluate this candidate for treating Cholangiocarcinoma (Bile Duct Cancer) which could be eligible for Orphan Drug status. Study data from this trial should be out in the first half of 2024.

Analyse de la rémunération des PDG

Comment la rémunération de M. Prigent a-t-elle évolué par rapport aux bénéfices de Genfit?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2025n/an/a

-€39m

Mar 31 2025n/an/a

-€19m

Dec 31 2024€682k€406k

€2m

Sep 30 2024n/an/a

€12m

Jun 30 2024n/an/a

€22m

Mar 31 2024n/an/a

-€3m

Dec 31 2023€664k€394k

-€29m

Sep 30 2023n/an/a

-€32m

Jun 30 2023n/an/a

-€34m

Mar 31 2023n/an/a

-€29m

Dec 31 2022€632k€375k

-€24m

Sep 30 2022n/an/a

€12m

Jun 30 2022n/an/a

€48m

Mar 31 2022n/an/a

€58m

Dec 31 2021€562k€325k

€67m

Sep 30 2021n/an/a

€14m

Jun 30 2021n/an/a

-€39m

Mar 31 2021n/an/a

-€70m

Dec 31 2020€455k€325k

-€101m

Sep 30 2020n/an/a

-€84m

Jun 30 2020n/an/a

-€67m

Mar 31 2020n/an/a

-€66m

Dec 31 2019€325k€95k

-€65m

Rémunération vs marché: La rémunération totale de M. ($USD 792.04K ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 2.64M ).

Rémunération et revenus: La rémunération de M. a augmenté alors que l'entreprise n'est pas rentable.

PDG

M. Prigent (57 yo)

6.5yrs
Titularisation
€681,945
Compensation

Mr. M. Pascal Prigent has been Chief Executive Officer of Genfit SA since September 16, 2019. He served as Executive Vice President of Marketing & Commercial Development at Genfit SA since May 31, 2018 unt...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Jean-Francois Mouney
Co-Founder & Chairman of the Board8.8yrs€382.68k0.094%
$ 506.5k
M. Prigent
Chief Executive Officer6.5yrs€681.95k0.062%
$ 333.8k
Bart Staels
Co-Founder & Chairman of the Scientific Advisory Boardno datapas de donnéespas de données
Thomas Baetz
Chief Financial Officer4.9yrspas de donnéespas de données
Pascal Caisey
Chief Operating Officer4yrspas de données0.0030%
$ 16.3k
Sakina Sayah-Jeanne
Chief Scientific Officerless than a yearpas de donnéespas de données
Jean-Christophe Marcoux
Chief Corporate Affairs Officer3yrspas de données0.0094%
$ 50.8k
Laurent Lannoo
Corporate Secretary & Director of Legal Affairs18.2yrspas de données0.023%
$ 122.1k
Stefanie Magner
Chief Compliance Officer & Executive VP of International Legal Affairs5yrspas de données0.0055%
$ 30.0k
Emilie Desodt
Executive Vice President of Human Resources4yrspas de données0.00047%
$ 2.5k
John Brozek
Executive Vice President of Data & Information Technology3yrspas de données0.0060%
$ 32.7k
Tom Huijbers
Executive Vice President of Regulatory3yrspas de donnéespas de données
4.0yrs
Durée moyenne de l'emploi
53yo
Âge moyen

Gestion expérimentée: L'équipe de direction de GNFT.Y est considérée comme expérimentée (ancienneté moyenne 4 ans).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Jean-Francois Mouney
Co-Founder & Chairman of the Board8.8yrs€382.68k0.094%
$ 506.5k
Bart Staels
Co-Founder & Chairman of the Scientific Advisory Boardno datapas de donnéespas de données
Philippe Moons
Board Observer5.1yrs€14.17k0.0021%
$ 11.3k
Florence Séjourné
Director8.8yrspas de donnéespas de données
Scott L. Friedman
Member of Scientific Advisory Boardno datapas de donnéespas de données
Arun Sanyal
Member of Scientific Advisory Boardno datapas de donnéespas de données
Michael Trauner
Member of Scientific Advisory Boardno datapas de donnéespas de données
Catherine Larue
Independent Director8.8yrs€50.14kpas de données
Vlad Ratziu
Member of Scientific Advisory Boardno datapas de donnéespas de données
Anne-Helene Monsellato
Independent Director8.8yrs€45.78kpas de données
Katherine Kalin
Independent Director5.7yrs€38.39k0.010%
$ 54.3k
Eric Baclet
Independent Vice-Chairman of the Board5.7yrs€68.42k0.0024%
$ 13.0k
8.8yrs
Durée moyenne de l'emploi
63yo
Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de GNFT.Y sont considérés comme expérimentés (ancienneté moyenne 8.8 ans).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/03/11 08:48
Cours de l'action en fin de journée2026/03/09 00:00
Les revenus2025/06/30
Revenus annuels2024/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Genfit S.A. est couverte par 14 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Geoffrey MeachamBofA Global Research
Arnaud CadartCIC Market Solutions (ESN)
Alethia YoungDeutsche Bank